The FDA-approved core fucosylated α-fetoprotein (AFP-L3) is widely used as an early diagnosis of hepatocellular carcinoma, and AFP-L3 is more specific than AFP (44). The gene discussed is AFP; the disease is hepatocellular carcinoma.